1. Williams RE, Adams HR, Blohm M, et al. Management strategies for CLN2 disease. Pediatr Neurol. 2017;69:102–12.
2. BioMarin Pharmaceutical. BRINEURA (cerliponase alfa): US prescribing information. 2017.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761052lbl.pdf
. Accessed 5 May 2017.
3. Eurpean Medicines Agency. Cerliponase alfa (Brineura): summary of product characteristics 2017.
http://ec.europa.eu/health/documents/community-register/2017/20170530137963/anx_137963_en.pdf
. Accessed 2 June 2017.
4. Gissen P, Schulz A, Specchio N, et al. Intracerebroventricular cerliponase alfa (BMN 190) in children with CLN2 disease: results from a phase 1/2, open-label, dose-escalation study (abstract). Dev Med Child Neurol. 2017;59(Suppl 1):7–8.
5. Schulz A, Specchio N, Gissen P, et al. Long-term safety and efficacy of intracerebroventricular enzyme replacement therapy with cerliponase alfa in children with CLN2 disease: interim results from an ongoing multicenter, multinational extension study (abstract no. 302). Mol Genet Metab. 2017;120(1–2):S120.